Diabetes patients could monitor glucose with lightwaves. Future versions of the noninvasive prototype may be as small as a watch. Breakthroughs, discoveries, and DIY tips sent every weekday. A new, noninvasive blood-glucose monitoring system may allow people with diabetes to finally ditch their painful finger pricks and under the skin sensors. Although the current iteration is comparatively bulky, MIT scientists writing in the journal say they are well on their way to scaling down their invention.

Diabetes is one of the most prevalent diseases worldwide, characterized by persistently high blood sugar levels, capable of damaging various internal organs and systems. Diabetes patients require routine check-ups, resulting in a time series of laboratory records, such as hemoglobin A1c, which reflects each patient's health behavior over time and informs their doctor's recommendations. Clustering patients into groups based on their entire time series data assists doctors in making recommendations and choosing treatments without the need to review all records. However, time series clustering of this type of dataset introduces some challenges; patients visit their doctors at different time points, making it difficult to capture and match trends, peaks, and patterns. Additionally, two aspects must be considered: differences in the levels of laboratory results and differences in trends and patterns. To address these challenges, we introduce a new clustering algorithm called Time and Trend Traveling Time Series Clustering (4TaStiC), using a base dissimilarity measure combined with Euclidean and Pearson correlation metrics. We evaluated this algorithm on artificial datasets, comparing its performance with that of seven existing methods. The results show that 4TaStiC outperformed the other methods on the targeted datasets. Finally, we applied 4TaStiC to cluster a cohort of 1,989 type 2 diabetes patients at Siriraj Hospital. Each group of patients exhibits clear characteristics that will benefit doctors in making efficient clinical decisions. Furthermore, the proposed algorithm can be applied to contexts outside the medical field.

The paper investigates the escalating concerns surrounding the surge in diabetes cases, exacerbated by the COVID-19 pandemic, and the subsequent strain on medical resources. The research aims to construct a predictive model quantifying factors influencing inpatient hospital stay durations for diabetes patients, offering insights to hospital administrators for improved patient management strategies. The literature review highlights the increasing prevalence of diabetes, emphasizing the need for continued attention and analysis of urban-rural disparities in healthcare access. International studies underscore the financial implications and healthcare burden associated with diabetes-related hospitalizations and complications, emphasizing the significance of effective management strategies. The methodology involves a quantitative approach, utilizing a dataset comprising 10,000 observations of diabetic inpatient encounters in U.S. hospitals from 1999 to 2008. Predictive modeling techniques, particularly Generalized Linear Models (GLM), are employed to develop a model predicting hospital stay durations based on patient demographics, admission types, medical history, and treatment regimen. The results highlight the influence of age, medical history, and treatment regimen on hospital stay durations for diabetes patients. Despite model limitations, such as heteroscedasticity and deviations from normality in residual analysis, the findings offer valuable insights for hospital administrators in patient management. The paper concludes with recommendations for future research to address model limitations and explore the implications of predictive models on healthcare management strategies, ensuring equitable patient care and resource allocation.

We propose a novel framework that combines deep generative time series models with decision theory for generating personalized treatment strategies. It leverages historical patient trajectory data to jointly learn the generation of realistic personalized treatment and future outcome trajectories through deep generative time series models. In particular, our framework enables the generation of novel multivariate treatment strategies tailored to the personalized patient history and trained for optimal expected future outcomes based on conditional expected utility maximization. We demonstrate our framework by generating personalized insulin treatment strategies and blood glucose predictions for hospitalized diabetes patients, showcasing the potential of our approach for generating improved personalized treatment strategies. Keywords: deep generative model, probabilistic decision support, personalized treatment generation, insulin and blood glucose prediction

For this smaller group of patients, physicians may have limited clinical decision-making experience or evidence-based guidance for choosing drug combinations. The solution is to expand the number of patients to support development of general principles to guide decision-making. Combining patient data from multiple healthcare institutions, however, requires deep expertise in artificial intelligence (AI) and wide-ranging experience in developing machine learning models using sensitive and complex healthcare data. Hitachi, U of U Health, and Regenstrief researchers partnered to develop and test a new AI method that analyzed electronic health record data across Utah and Indiana and learned generalizable treatment patterns of type 2 diabetes patients with similar characteristics. Those patterns can now be used to help determine an optimal drug regimen for a specific patient.

Researchers from Italy have created a robot that could one day allow diabetes patients to get a dose of insulin without any needles. PILLSID involves two separate parts. One component is an internal insulin dispenser that a doctor would surgically implant in your abdomen. The other is a magnetic capsule loaded with the hormone. Anytime you need to refill the dispenser, you take one of the pills, and it travels down your digestive system until it reaches the point where the device is implanted near your small intestine.

WASHINGTON--A type of artificial intelligence called machine learning can help predict which patients will develop diabetes, according to an ENDO 2020 abstract that will be published in a special supplemental section of the Journal of the Endocrine Society. Diabetes is linked to increased risks of severe health problems, including heart disease and cancer. Preventing diabetes is essential to reduce the risk of illness and death. "Currently we do not have sufficient methods for predicting which generally healthy individuals will develop diabetes," said lead author Akihiro Nomura, M.D., Ph.D., of the Kanazawa University Graduate School of Medical Sciences in Kanazawa, Japan. The researchers investigated the use of a type of artificial intelligence called machine learning in diagnosing diabetes.

The study was also presented at the Heart Failure Society of America Annual Scientific Meeting in Philadelphia. Type 2 diabetes is a global epidemic that is expected to affect over 592 million people globally by 2035, a dramatic increased from 382 million people with diabetes mellitus in 2013, a prevalence that is likely to be underestimated. Type 2 diabetes patients are at more than double the risk of developing heart failure resulting in disability or death among such patients. Earlier this month, late-breaking trial results revealed that a new class of medications known as SGLT2 inhibitors may be helpful for patients with heart failure. These therapies may also be used in patients with diabetes to prevent heart failure from occurring in the first place.

Heart failure is an important potential complication of type 2 diabetes that occurs frequently and can lead to death or disability. Earlier this month, late-breaking trial results revealed that a new class of medications known as SGLT2 inhibitors may be helpful for patients with heart failure. These therapies may also be used in patients with diabetes to prevent heart failure from occurring in the first place. However, a way of accurately identifying which diabetes patients are most at risk for heart failure remains elusive. A new study led by investigators from Brigham and Women's Hospital and UT Southwestern Medical Center unveils a new, machine-learning derived model that can predict, with a high degree of accuracy, future heart failure among patients with diabetes.

Heart failure is an important potential complication of type 2 diabetes that occurs frequently and can lead to death or disability. Earlier this month, late-breaking trial results revealed that a new class of medications known as SGLT2 inhibitors may be helpful for patients with heart failure. These therapies may also be used in patients with diabetes to prevent heart failure from occurring in the first place. However, a way of accurately identifying which diabetes patients are most at risk for heart failure remains elusive. A new study led by investigators from Brigham and Women's Hospital and UT Southwestern Medical Center unveils a new, machine-learning derived model that can predict, with a high degree of accuracy, future heart failure among patients with diabetes.